Hemant Surgical Industries Limited has announced receipt of a major purchase order worth ₹264.33 crores from the Central Medical Service Society (CMSS), Ministry of Health and Family Welfare, Government of India. The company disclosed this development through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Order Details and Specifications

The purchase order encompasses supply of sophisticated medical equipment including Flat Panel Detectors with two batteries and router, Hard Travel Case, and X-Ray Generators along with other utilities. The order value of ₹264.33 crores is inclusive of all taxes and duties, representing a significant business win for the medical equipment manufacturer.

Implementation Strategy

Despite final commercial terms and delivery schedules still being under discussion and finalization, Hemant Surgical Industries has agreed to commence supplies on an interim basis. This decision reflects the company's recognition of the national importance of the project and response to the specific request made by CMSS.

The order will be executed in tranches by September 30, 2026, subject to ongoing negotiations, terms, and any extensions that may be requested by the company to CMSS. This phased approach allows for systematic delivery while accommodating the finalization of remaining commercial terms.

Regulatory Compliance and Transparency

The company has confirmed that this order represents a domestic transaction with no related party implications. The promoter, promoter group, or group companies have no interest in the awarding entity, ensuring arm's length transaction principles are maintained.

Hemant Surgical Industries has committed to providing updates on the final commercial terms once they are concluded, maintaining transparency with stakeholders throughout the process. This substantial order reinforces the company's position in the medical equipment sector and its capability to serve critical healthcare infrastructure needs.

Hemant Surgical Industries Limited (ISIN: INE0GYI01028) has announced its unaudited financial results for the half year ended September 30, 2025, showcasing significant growth and strategic capital raising initiatives.

Financial Highlights

• Revenue Growth: The company reported revenue from operations of ₹64.26 crore for H1 FY2026, marking a 31.5% increase from ₹48.87 crore in the corresponding period of the previous year.
• Profitability: Basic earnings per share (EPS) stood at ₹5.09, up from ₹3.05 in the prior year period, indicating improved profitability.

Capital Raising and Utilization

Hemant Surgical Industries has successfully raised ₹61.53 crore through a preferential allotment, comprising:

• 25,98,400 equity shares at ₹197 per share
• 20,99,200 convertible warrants

The total proceeds, including the full conversion of warrants, are allocated as follows:

As of September 30, 2025, the company has utilized ₹15.43 crore of the raised funds. The remaining ₹46.09 crore is held in bank accounts, with an additional ₹31.02 crore expected from warrant holders upon conversion.

Operational Performance

The company's strong revenue growth suggests improved market demand for its products. The significant increase in EPS indicates enhanced operational efficiency and cost management.

Future Outlook

With the recent capital infusion, Hemant Surgical Industries is well-positioned to execute its expansion plans. The allocation of funds towards new facilities, working capital, and debt repayment is expected to strengthen the company's operational capabilities and financial position.

Management Commentary

While specific management comments were not provided, the strategic allocation of funds towards expansion and working capital suggests a focus on growth and operational enhancement.

Investors and stakeholders will likely be watching closely to see how effectively the company deploys its newly raised capital to drive future growth and maintain its positive momentum in the coming quarters.